An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

237

Participants

Timeline

Start Date

October 11, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Advanced Solid Tumor
Interventions
DRUG

BGB-58067

Planned doses administered on specified days per protocol.

DRUG

BG-89894

Planned doses administered on specified days per protocol.

DRUG

Standard of Care Therapy

Administered in accordance with relevant local guidelines and/or prescribing information.

Trial Locations (45)

2100

RECRUITING

Rigshospitalet, Copenhagen

13009

NOT_YET_RECRUITING

Institut Paoli Calmettes, Marseille

22031

RECRUITING

Next Virginia, Fairfax

28040

RECRUITING

Hospital Clinico San Carlos, Madrid

RECRUITING

Start Madrid Fundacion Jimenez Diaz, Madrid

28050

RECRUITING

Hospital Universitario Hm Madrid Sanchinarro, Madrid

33000

RECRUITING

Centre de Lutte Contre Le Cancer Institut Bergonie, Bordeaux

44800

NOT_YET_RECRUITING

Institut de Cancerologie de Louest, Saint-Herblain

75005

RECRUITING

Institut Curie Paris, Paris

94800

RECRUITING

Institut Gustave Roussy, Villejuif

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

100142

RECRUITING

Beijing Cancer Hospital, Beijing

110001

NOT_YET_RECRUITING

The First Hospital of China Medical University, Shenyang

150000

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

200123

RECRUITING

Shanghai East Hospital Branch Hospital, Shanghai

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

201321

RECRUITING

Fudan University Shanghai Cancer Centerpudong, Shanghai

210029

NOT_YET_RECRUITING

Jiangsu Province Hospital, Nanjing

230601

NOT_YET_RECRUITING

The Second Hospital of Anhui Medical University, Hefei

310003

NOT_YET_RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

310022

NOT_YET_RECRUITING

Zhejiang Cancer Hospital, Hangzhou

330029

NOT_YET_RECRUITING

Jiangxi Cancer Hospital, Nanchang

350014

RECRUITING

Fujian Cancer Hospital, Fuzhou

430022

NOT_YET_RECRUITING

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

450000

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

450052

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510060

RECRUITING

Sun Yat Sen University Cancer Center, Guangzhou

610041

NOT_YET_RECRUITING

West China Hospital, Sichuan University, Chengdu

90089-1019

RECRUITING

Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles

34747-4606

RECRUITING

Adventhealth, Celebration

02215-5418

RECRUITING

Dana Farber Cancer Institute, Boston

63110-1010

RECRUITING

Washington University School of Medicine, St Louis

10016-2708

NOT_YET_RECRUITING

Nyu Langone Health, New York

19107-4307

RECRUITING

Sidney Kimmel Cancer Center, Philadelphia

77030-4009

RECRUITING

The University of Texas Md Anderson Cancer Center, Houston

75039-2743

RECRUITING

Next Dallas, Irving

NSW 2148

RECRUITING

Blacktown Cancer and Haematology Centre, Blacktown

VIC 3168

RECRUITING

Monash Health, Clayton

VIC 3084

RECRUITING

Austin Health, Heidelberg

WA 6009

RECRUITING

Linear Clinical Research, Nedlands

06351

RECRUITING

Samsung Medical Center, GangnamGu

03722

RECRUITING

Severance Hospital Yonsei University Health System, SeodaemunGu

03080

RECRUITING

Seoul National University Hospital, Seoul

05505

RECRUITING

Asan Medical Center, SongpaGu

08035

RECRUITING

Hospital Universitario Vall Dhebron, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT06589596 - An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter